v3.26.1
Statements of Consolidated Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Profit or loss [abstract]      
Revenues $ 72,949 $ 41,505 $ 755
Other income 6,644 7,712 8,438
Total revenues and other income 79,592 49,217 9,193
Operating expenses      
Cost of revenue 0 0 (737)
Research and development expenses (93,517) (90,536) (87,646)
Selling, general and administrative expenses (19,790) (19,085) (16,812)
Other operating income (expenses) 638 849 (1,300)
Total operating expenses and other operating income (112,669) (108,771) (106,495)
Operating income (loss) (33,076) (59,554) (97,302)
Financial income 16,124 44,407 21,479
Financial expenses (51,064) (21,614) (40,642)
Net Financial gain (loss) (34,940) 22,793 (19,163)
Tax income (expense) 423 0 (371)
Income (loss) from continuing operations (67,593) (36,761) (116,835)
Income (loss) from discontinued operations 0 0 8,392
Net income (loss) (67,593) (36,761) (108,443)
Attributable to shareholders of Cellectis (67,593) (36,761) (101,059)
Attributable to non-controlling interests $ 0 $ 0 $ (7,384)
Basic / Diluted net income (loss) per share attributable to shareholders of Cellectis      
Basic net income (loss) attributable to shareholders of Cellectis, per share ($ /share) $ (0.67) $ (0.41) $ (1.77)
Diluted net income (loss) attributable to shareholders of Cellectis, per share ($ /share) (0.67) (0.41) (1.77)
Basic net income (loss) attributable to shareholders of Cellectis from discontinued operations, per share ($ /share) 0 0 0.28
Diluted net income (loss) attributable to shareholders of Cellectis from discontinued operations, per share ($ /share) $ 0 $ 0 $ 0.28
Number of shares used for computing      
Basic 100,279,276 90,566,346 57,012,815
Diluted 100,279,276 90,566,346 57,012,815